A detailed history of Legal & General Group PLC transactions in X Biotech Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 1,598 shares of XBIT stock, worth $10,642. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,598
Previous 1,598 -0.0%
Holding current value
$10,642
Previous $12,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.54 - $9.89 $7,254 - $15,804
1,598 New
1,598 $8,000
Q3 2022

Nov 14, 2022

SELL
$3.58 - $5.88 $4,500 - $7,391
-1,257 Closed
0 $0
Q2 2022

Aug 22, 2022

SELL
$5.13 - $9.2 $19,345 - $34,693
-3,771 Reduced 75.0%
1,257 $7,000
Q3 2021

Nov 15, 2021

BUY
$12.95 - $18.24 $46,917 - $66,083
3,623 Added 257.86%
5,028 $65,000
Q2 2021

Aug 12, 2021

SELL
$15.83 - $17.84 $15,022 - $16,930
-949 Reduced 40.31%
1,405 $23,000
Q1 2021

May 17, 2021

BUY
$15.92 - $20.3 $17,464 - $22,269
1,097 Added 87.27%
2,354 $41,000
Q3 2020

Nov 13, 2020

SELL
$13.97 - $21.16 $8,773 - $13,288
-628 Reduced 33.32%
1,257 $24,000
Q2 2020

Aug 14, 2020

SELL
$10.39 - $16.07 $2,285 - $3,535
-220 Reduced 10.45%
1,885 $26,000
Q1 2020

May 14, 2020

SELL
$8.89 - $24.94 $16,810 - $47,161
-1,891 Reduced 47.32%
2,105 $22,000
Q4 2019

Feb 13, 2020

BUY
$8.33 - $19.95 $3,165 - $7,581
380 Added 10.51%
3,996 $75,000
Q3 2019

Nov 13, 2019

BUY
$6.86 - $10.46 $5,721 - $8,723
834 Added 29.98%
3,616 $38,000
Q2 2019

Aug 14, 2019

BUY
$6.99 - $11.27 $19,446 - $31,353
2,782 New
2,782 $21,000
Q2 2018

Aug 10, 2018

SELL
$4.04 - $5.13 $11,396 - $14,471
-2,821 Closed
0 $0
Q1 2018

May 17, 2018

SELL
$3.92 - $5.35 $10,591 - $14,455
-2,702 Reduced 48.92%
2,821 $15,000
Q4 2017

Feb 13, 2018

BUY
$3.9 - $4.66 $21,539 - $25,737
5,523
5,523 $22,000

Others Institutions Holding XBIT

About XBiotech Inc.


  • Ticker XBIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,439,300
  • Market Cap $203M
  • Description
  • XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...
More about XBIT
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.